DK3146970T3 - Nukleinsyrelægemiddel til induktion af overspringning af en exonvariant af CD44-genet og øgning af ekspression af CD44-mRNA af normal type - Google Patents

Nukleinsyrelægemiddel til induktion af overspringning af en exonvariant af CD44-genet og øgning af ekspression af CD44-mRNA af normal type Download PDF

Info

Publication number
DK3146970T3
DK3146970T3 DK15796807.4T DK15796807T DK3146970T3 DK 3146970 T3 DK3146970 T3 DK 3146970T3 DK 15796807 T DK15796807 T DK 15796807T DK 3146970 T3 DK3146970 T3 DK 3146970T3
Authority
DK
Denmark
Prior art keywords
mrna
gene
nucleic acid
normal type
acid drug
Prior art date
Application number
DK15796807.4T
Other languages
English (en)
Inventor
Masafumi Matsuo
Seiji Matsuda
Original Assignee
Knc Laboratories Co Ltd
Kobe Gakuin Educational Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knc Laboratories Co Ltd, Kobe Gakuin Educational Found filed Critical Knc Laboratories Co Ltd
Application granted granted Critical
Publication of DK3146970T3 publication Critical patent/DK3146970T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK15796807.4T 2014-05-19 2015-05-13 Nukleinsyrelægemiddel til induktion af overspringning af en exonvariant af CD44-genet og øgning af ekspression af CD44-mRNA af normal type DK3146970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014103674 2014-05-19
PCT/JP2015/063810 WO2015178277A1 (ja) 2014-05-19 2015-05-13 ＣＤ４４遺伝子のバリアントエクソンのスキッピングを誘導し、正常型ＣＤ４４ｍＲＮＡの発現を増加させる核酸医薬

Publications (1)

Publication Number Publication Date
DK3146970T3 true DK3146970T3 (da) 2022-12-05

Family

ID=54553950

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15796807.4T DK3146970T3 (da) 2014-05-19 2015-05-13 Nukleinsyrelægemiddel til induktion af overspringning af en exonvariant af CD44-genet og øgning af ekspression af CD44-mRNA af normal type

Country Status (7)

Country Link
US (1) US10174319B2 (da)
EP (1) EP3146970B1 (da)
JP (1) JP6536911B2 (da)
CA (1) CA2948139A1 (da)
DK (1) DK3146970T3 (da)
ES (1) ES2930274T3 (da)
WO (1) WO2015178277A1 (da)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170637A1 (en) 2002-03-06 2003-09-11 Pirrung Michael C. Method of analyzing mRNA splice variants
US7842459B2 (en) * 2004-01-27 2010-11-30 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US20080171042A1 (en) * 2004-05-07 2008-07-17 University Of Florida Research Foundation, Inc. Cd44 Variants As Therapeutic Targets
WO2006059507A1 (ja) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1アンチセンス化合物
WO2008029619A1 (fr) * 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CN117721110A (zh) 2011-12-28 2024-03-19 日本新药株式会社 反义核酸

Also Published As

Publication number Publication date
EP3146970A4 (en) 2017-12-13
CA2948139A1 (en) 2015-11-26
JPWO2015178277A1 (ja) 2017-04-20
EP3146970A1 (en) 2017-03-29
WO2015178277A1 (ja) 2015-11-26
ES2930274T3 (es) 2022-12-09
US20170137810A1 (en) 2017-05-18
EP3146970B1 (en) 2022-11-02
JP6536911B2 (ja) 2019-07-03
US10174319B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
DK3341482T3 (da) Kunstige nukleinsyremolekyler
BR112017008877A2 (pt) métodos e composições para sequenciamento de ácido nucleico-alvo
DK3690056T5 (da) Fremgangsmåder og produkter til fremstilling og indgivelse af nukleinsyre
DK3368678T3 (da) Genetisk konstrukt
DK3198035T3 (da) Fremgangsmåder til forudsigelse af medicinrespons
DK3262066T4 (da) Genterapi
DK3374525T3 (da) Højeffektiv konstruktion af dna-biblioteker
DK3129487T3 (da) Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
DK3102722T3 (da) Genom fraktionering
DK3161154T3 (da) Modificerede polymeraser til forbedret inkorporering af nukleotidanaloger
DK3213084T4 (da) Fremgangsmåde til berigelse af cirkulerende tumor dna
DK3351633T3 (da) Antisense-nukleinsyre
DK3094731T3 (da) Saccharidmodificerede nukleinsyremolekyler
BR112017007282A2 (pt) métodos, sistemas e processos de montagem de novo de leituras de sequenciamento
DK3149124T3 (da) Anvendelse af lavmolekylære imid-holdige kvaternære ammoniumsalte
DK3334576T3 (da) Stavelement
DK3298162T3 (da) Detektering af målnukleinsyre og varianter
DK3137053T3 (da) Formuleringer af biologiske lægemidler til intravesikal instillation
DK3270993T3 (da) Respiratorer
DK3224356T3 (da) Metoder til rekombinant udtrykkelse af beta-glucosidase-gen
DK3105340T3 (da) Opdeling af DNA-sekventeringsbiblioteker i værts- og mikrobielle komponenter
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
DK3133923T3 (da) Aav-based gene therapy for multiple sclerosis
DK3837970T3 (da) Herbicidtolerancegener og fremgangsmåder til anvendelse deraf
DK3184506T3 (da) Kationisk lipid til levering af nukleinsyre.